The impact of pharmacy-based screening on identification of unknown kidney disease and a quality use of medicines intervention on inappropriate medication use in people at risk for or living with chronic kidney disease

The University of Sydney0 个研究点目标入组 3,660 人开始时间: 2022年2月22日最近更新: 2023年2月27日

适应症

试验速览

暂无简介。

•Participants who are eligible for screening must:
•Be aged between 35 to 74 years
•Have at least one risk factor for CKD, such as hypertension, diabetes, cardiovascular conditions, family history of CKD, previous acute kidney injury, smoker, obese, Aboriginal or Torres Strait Islander, over the age of 60 years
•Be able to make independent decisions about their health and are willing to provide informed consent
•Not have kidney failure or not be receiving kidney replacement therapy
•People with earlier stages of CKD (i.e., stage 1-4) will be included in the study for the assessment of quality use of medicines, which is one of the primary outcomes of this study.
•Pharmacies will be eligible to participate if:
•They are from identified common hotspot areas for kidney disease
•They are approved to dispense PBS medicines
•They have a separate or private counselling area
•They have FRED/Z dispensing software
•They are accredited by an approved pharmacy accreditation program
•Willing to complete a baseline survey of existing screening and QUM services in kidney disease conducted prior to participating in the trial

发起方